EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 37 / No 5 (Mai 2021) Med Sci (Paris), 37 5 (2021) 491-499 References
Free Access
Issue
Med Sci (Paris)
Volume 37, Number 5, Mai 2021
La révolution médicale du dépistage néonatal – Une aventure médicale scientifique et sociétale
Page(s) 491 - 499
Section La révolution médicale du dépistage néonatal – Une aventure médicale scientifique et sociétale
DOI https://doi.org/10.1051/medsci/2021051
Published online 18 May 2021
  1. Wilson JMG, Jungner G. Principles and practice of screening for disease disease. Public health papers n° 34. Geneva : World Health Organization, 1968. https://apps.who.int/iris/bitstream/handle/10665/37650/WHO_PHP_34.pdf?sequence=17. [Google Scholar]
  2. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull WHO 2008 ; 86 : 317–319. [Google Scholar]
  3. Rosenthal M. Newborn screening for cystic fibrosis: the motion against; voices in the wilderness. Paediatr Respir Rev 2008 ; 9 : 295–300. [CrossRef] [PubMed] [Google Scholar]
  4. Tridello G, Castellani C, Meneghelli I, et al. Early diagnosis from newborn screening maximises survival in severe cystic fibrosis. ERJ Open Res 2018; 4. [Google Scholar]
  5. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin cystic fibrosis neonatal screening study group. Pediatrics 2001 ; 107 : 1–13. [CrossRef] [PubMed] [Google Scholar]
  6. Chatfield S, Owen G, Ryley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child 1991 ; 66 : 29–33. [CrossRef] [PubMed] [Google Scholar]
  7. Mérelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001 ; 18 : 306–315. [CrossRef] [PubMed] [Google Scholar]
  8. Mastella G, Zanolla L, Castellani C, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology 2001 ; 1 : 531–537. [CrossRef] [PubMed] [Google Scholar]
  9. Siret D, Bretaudeau G, Branger B, et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol 2003 ; 35 : 342–349. [CrossRef] [PubMed] [Google Scholar]
  10. Wang SS, O’Leary LA, Fitzsimmons SC, Khoury MJ. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002 ; 141 : 804–810. [CrossRef] [PubMed] [Google Scholar]
  11. Lai HJ, Cheng Y, Cho Het al. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol 2004 ; 159 : 537–546. [CrossRef] [PubMed] [Google Scholar]
  12. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004 ; 53 : 1–36. [PubMed] [Google Scholar]
  13. Castellani C, Southern KW, Brownlee K, et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009 ; 8 : 153–173. [CrossRef] [PubMed] [Google Scholar]
  14. Barben J, Castellani C, Dankert-Roelse J, et al. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. J Cyst Fibros 2017 ; 16 : 207–213. [CrossRef] [PubMed] [Google Scholar]
  15. Claustres M, Guittard C, Bozon D, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat 2000 ; 16 : 143–156. [CrossRef] [PubMed] [Google Scholar]
  16. Nguyen-Khoa T, Borgard JP, Marchand M, et al. Analytical quality of assays and comparison of procedures for the sweat test. Ann Biol Clin 2012 ; 70 : 5–12. [Google Scholar]
  17. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018 ; 17 : 153–178. [CrossRef] [PubMed] [Google Scholar]
  18. Farrell PM, White TB, Howenstine MS, et al. Diagnosis of cystic fibrosis in screened populations. J Pediatr 2017; 181S : S33–44e2. [CrossRef] [PubMed] [Google Scholar]
  19. Munck A, Delmas D, Audrezet MP, et al. Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process. J Med Screen 2018 ; 25 : 6–12. [CrossRef] [PubMed] [Google Scholar]
  20. Thauvin-Robinet C, Munck A, Huet F, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 2009 ; 46 : 752–758. [CrossRef] [PubMed] [Google Scholar]
  21. Smyth AR, Bell SC, Bojcin S, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros 2014 ; 13(suppl 1): S23–S42. [CrossRef] [PubMed] [Google Scholar]
  22. Audrézet MP, Munck A. Newborn screening for CF in France: an exemplary national experience. Arch Pediatr 2020; 27 (suppl 1) : eS35-40. [CrossRef] [PubMed] [Google Scholar]
  23. Audrezet MP, Munck A, Scotet V, et al. Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy. Genet Med 2015 ; 17 : 108–116. [CrossRef] [PubMed] [Google Scholar]
  24. Castellani C, Massie J. Emerging issues in cystic fibrosis newborn screening. Curr Opin Pulm Med 2010 ; 16 : 584–590. [CrossRef] [PubMed] [Google Scholar]
  25. Roussey M, Beucher J, Leray E. Effect of false positive results in CF newborn screening on parental stress. Pediatr Pulmonol 2008 ; 31(suppl): 450–451. [Google Scholar]
  26. Munck A, Houssin E, Roussey M. The importance of sweat testing for older siblings of patients with cystic fibrosis identified by newborn screening. J Pediatr 2009 ; 155 : 928–930. [CrossRef] [PubMed] [Google Scholar]
  27. Munck A, Mayell SJ, Winters V, et al. Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 2015 ; 14 : 706–713. [CrossRef] [PubMed] [Google Scholar]
  28. Southern KW, Barben J, Gartner S, et al. Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis - Clarification of the harmonised international definition. J Cyst Fibros 2019 ; 18 : 778–780. [CrossRef] [PubMed] [Google Scholar]
  29. Ren CL, Fink AK, Petren K, et al. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. Pediatrics 2015 ; 135 : e1386–e1392. [CrossRef] [PubMed] [Google Scholar]
  30. Ooi CY, Castellani C, Keenan K, et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 2015 ; 135 : e1377–e1385. [CrossRef] [PubMed] [Google Scholar]
  31. Munck A, Bourmaud A, Bellon G, et al. Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening. Pediatr Pulmonol 2020; 55 : 918–28. [CrossRef] [PubMed] [Google Scholar]
  32. Sermet-Gaudelus I, Brouard J, Audrezet MP, et al. Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening. Arch Pediatr 2017 ; 24 : e1–14. [CrossRef] [PubMed] [Google Scholar]
  33. Barben J, Castellani C, Munck A, et al. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). J Cyst Fibros 2020; S1569–1993 : 30909–7. [Google Scholar]
  34. Claustres M, Theze C, des Georges M, et al. CFTR-France, a national relational patient database for sharing genetic and phenotypic data associated with rare CFTR variants. Hum Mutat 2017; 38 : 1297–315. [CrossRef] [PubMed] [Google Scholar]
  35. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011 ; 365 : 1663–1672. [CrossRef] [PubMed] [Google Scholar]
  36. Munck A, Cheillan D, Girodon E, et al. Newborn screening for cystic fibrosis in France: practical aspects and perspectives. Perf Pediatr 2019 ; 2 : 63–71. [Google Scholar]
  37. Protocole National de Diagnostic et de Soins (PNDS). https://www.has-sante.fr/jcms/c_1340879/fr/protocoles-nationaux-de-diagnostic-et-de-soins-pnds. [Google Scholar]
  38. Sarles J, Giorgi R, Berthézène P, et al. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP. J Cyst Fibros 2014 ; 13 : 384–390. [CrossRef] [PubMed] [Google Scholar]
  39. Dijk FN, Fitzgerald DA. The impact of newborn screening and earlier intervention on the clinical course of cystic fibrosis. Paediatr Respir Rev 2012 ; 13 : 220–225. [CrossRef] [PubMed] [Google Scholar]
  40. Coffey MJ, Whitaker V, Gentin N, et al. Differences in outcomes between early and late diagnosis of cystic fibrosis in the newborn screening era. J Pediatr 2017; 181 : 137–45e1. [CrossRef] [PubMed] [Google Scholar]
  41. Sims EJ, Mugford M, Clark A, et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007 ; 369 : 1187–1195. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.